Showing 1761-1770 of 20417 results for "".
Managing RVO: Goals of Early Intervention
https://reachmd.com/programs/eye-on-ocular-health/managing-rvo-goals-of-early-intervention/54487/Retinal vein occlusion (RVO) can lead to significant vision loss when macular edema and ischemic complications are not recognized and treated early. Hear Dr. Michael Javaheri discuss the burden of RVO, key treatment goals, and how newer anti-VEGF therapies may help improve durability while reducingImproving CRC Screening Workflows: A PCP's Recommendations
https://reachmd.com/programs/clinicians-roundtable/improving-crc-screening-workflows-a-pcps-recommendations/56456/Colorectal cancer (CRC) screening is most effective when it fits seamlessly into busy primary care workflows while still keeping patients engaged in the process. Join Dr. Natalia Usoltseva as she discusses practical ways to improve screening, from simplifying shared decision-making conversations andBoosting Colorectal Cancer Screening in Rural Clinics: Insights from SMARTER CRC
https://reachmd.com/programs/clinicians-roundtable/boosting-colorectal-cancer-screening-in-rural-clinics-insights-from-smarter-crc/36409/The SMARTER CRC trial evaluated mailed fecal immunochemical (FIT) outreach and patient navigation strategies across rural clinics, analyzing how implementation factors like clinic-sent letters, consistent FIT usage, and active participation in health plan meetings impacted screening outcomes. Two auBehind the Breakout: Acne as a Meaningful Side Effect of JAK Inhibitors for IBD
https://reachmd.com/programs/Audioabstracts/jak-inhibitors-acne-side-effect-ibd/49088/As JAK inhibitors become more widely used in treating inflammatory bowel disease (IBD), a new challenge is emerging: acne. That’s why Ryan Quigley spotlights the largest international cohort study to date examining JAK inhibitor-associated acne across more than 2,000 patients. Tune in to learn how fObesity and Asthma: Intersecting Pathways and Real-World Impacts
https://reachmd.com/programs/clinicians-roundtable/obesity-asthma-poor-disease-control/54181/Emerging evidence highlights a complex, bidirectional relationship between obesity and asthma, driven by shared genetics, epigenetic influences, environmental exposures, and metabolic dysfunction. Learn more with Dr. Anne Dixon, who’s a pulmonologist, professor, and the E. L. Amidon Chair of the DepAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
https://reachmd.com/programs/neurofrontiers/program-name/36465/Over the past two decades, Alzheimer’s diagnosis has transformed from uncertain, exclusion-based methods to more accurate detection of disease pathology. With the advent of amyloid PET tracers, cerebrospinal fluid and plasma biomarkers like p-tau 217, and the promise of AI-driven imaging analysis, cThe Far-Reaching Impacts of Psoriasis: Understanding and Mitigating Risks
https://reachmd.com/programs/dermconsult/the-far-reaching-impacts-of-psoriasis-understanding-and-mitigating-risks/32452/Hear how psoriasis can impact a patient’s health beyond their skin and how to best support them to improve outcomes and minimize risks.Genetics in Psoriasis: Impacts on Risk, Comorbidities, and Care
https://reachmd.com/programs/frontlines-psoriasis/genetics-in-psoriasis-impacts-on-risk-comorbidities-and-care/32435/Genetic insights are reshaping how we understand the development and comorbidities of psoriasis, as well as treatment response in patients. Hear Dr. Audrey Bui discuss how genetic variants influence risks for certain conditions, how they may predict response to therapies like methotrexate, ustekinumOne Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
https://reachmd.com/programs/project-oncology/one-year-or-two-dante-trial-explores-immunotherapy-duration-in-metastatic-melanoma/33002/The DANTE phase III trial investigated if stopping anti–PD-1 therapy at one year yields comparable outcomes to longer treatment in metastatic melanoma. Read more about the findings and their potential clinical implications.Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
https://reachmd.com/programs/frontlines-prostate-cancer/personalizing-prostate-cancer-surveillance-insights-from-canary-pass/32224/For patients with early-stage prostate cancer, routine clinical variables like Gleason scores or PSAs have their limits. The Canary Prostate Active Surveillance Study (Canary PASS) is reshaping our management approach through improved risk stratification. Dr. Lisa Newcomb joins us to explain the fin